文献速递免疫规划

一种基于甲病毒的新型自我扩增RNA平台:增强疫苗接种效力与器官特异性靶向

A novel alphavirus-based saRNA platform for enhanced vaccination efficacy and organ-specific targeting.
PubMed 文献 · Vaccine · 2025-12-04

研究系统优化了基于委内瑞拉马脑炎病毒(VEEV)的自我扩增RNA(saRNA),使蛋白表达较野生型提高10倍以上;体外筛选28种甲病毒来源的saRNA构建体,选出EVEV、MDPV和RNV三种用SM102脂质纳米颗粒(LNP)体内评估,显示持续表达、较强但可耐受的免疫原性及明显的肝外组织特异性分布,尤其在脾脏靶向方面优于传统mRNA。

要点

  • 优化VEEV saRNA的加帽结构、核苷酸修饰、polyA尾长度和调控元件,蛋白表达较野生型提高10倍以上。
  • 体外筛选28种甲病毒saRNA构建体,选EVEV、MDPV和RNV用SM102 LNP体内评估。
  • 优化saRNA在脾脏靶向方面显著高于传统mRNA,并展现肝外组织特异性分布。

核心结论

  • 优化后的saRNA平台在小鼠和兔体内诱导的免疫应答较线性mRNA更强且更一致。
  • 器官特异性表达谱为靶向RNA治疗提供新策略,与先进递送技术整合可能提升mRNA治疗的精确性、疗效和治疗潜力。

研究设计与样本

  • 研究系统优化基于VEEV的saRNA的加帽结构、核苷酸修饰、polyA尾长度和调控元件。
  • 体外筛选28种甲病毒来源的saRNA构建体,选出EVEV、MDPV和RNV三种候选。
  • 用SM102脂质纳米颗粒(LNP)制剂和荧光素酶报告基因在体内评估候选saRNA。
  • 在小鼠和兔体内进行免疫研究,比较EVEV saRNA与线性mRNA的免疫应答。

主要发现

  • 优化后saRNA蛋白表达较野生型提高10倍以上。
  • 优化saRNA表现出持续表达、较强但可耐受的免疫原性、明显的肝外组织特异性生物分布,脾脏靶向显著高于传统mRNA。
  • 该平台已针对难表达的多重跨膜抗原hCCR9和鼠TSCOT验证抗体开发。
  • 小鼠和兔体内免疫研究显示,EVEV saRNA诱导的免疫应答较线性mRNA更强且更一致。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Self-amplifying RNA (saRNA), derived from alphaviruses, encodes nonstructural proteins (NSP1-4) that form a replicase complex, enabling prolonged and amplified protein expression at lower doses than conventional mRNA. However, its high immunogenicity and limited replication efficiency require optimization for improved protein expression. Here, we systematically optimized a Venezuelan Equine Encephalitis Virus (VEEV)-based saRNA by refining its capping structure, nucleotide modifications, polyA tail length, and regulatory elements, achieving over 10-fold enhancement in protein expression compared to the wild-type. Additionally, we screened 28 alphavirus-derived saRNA constructs in vitro, selecting the top 3 candidates Everglades virus (EVEV), Mosso das Pedras virus (MDPV), and Rio Negro virus (RNV) for in vivo evaluation using SM102 lipid nanoparticle (LNP) formulations and luciferase reporters. These optimized saRNAs demonstrated sustained expression, stronger but tolerable immunogenicity, distinct extrahepatic tissue-specific biodistribution, and notably high spleen targeting compared to conventional mRNA. This novel saRNA platform has been validated for antibody development targeting challenging multi-pass transmembrane antigens hCCR9 and murine TSCOT. In vivo immunization studies in mice and rabbits demonstrated that EVEV-based saRNA induces stronger and more consistent immune responses compared to linear mRNA. Such organ-specific expression profiles present novel strategies for targeted RNA therapeutics, and further integration with advanced delivery technologies could enhance the precision, efficacy, and therapeutic potential of mRNA-based treatments.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sun Z, Liu Y, Zhang H, et al. A novel alphavirus-based saRNA platform for enhanced vaccination efficacy and organ-specific targeting. Vaccine. 2025. PMID: 41349243. doi:10.1016/j.vaccine.2025.128055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。